HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)
CIN: L74930TG2006PLC050223
Regd. Office: Plot No.19-III, Road No.71, Jubilee Hills,
Opp. Bharatiya Vidya Bhavan Public School, Hyderabad – 500096
Contact no – 40 - 6628 8888 | Email – cs@haleoslabs.com | Website: www.haleoslabs.com

NOTICE OF POSTAL BALLOT

[Pursuant to Section 110 of the Companies Act, 2013 read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014]

VOTING STARTS ON	VOTING ENDS ON
Thursday, 30th July, 2026 at 09.00 am (IST)	Friday, 28th August, 2026 at 05.00 pm (IST)

Dear Shareholders,

NOTICE is hereby given to the members of Haleos Labs Limited (Formerly known as "SMS Lifesciences India Limited") **("the Company")** pursuant to Section 108 and 110 and other applicable provisions, if any, of the Companies Act, 2013 (**"Act"**) and Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 (**"Rules"**) as amended from time to time, read with the General Circular No. 03/2025 dated 22nd September, 2025 and such other relevant previous circulars as were issued by the Ministry of Corporate Affairs pertaining to holding of General Meetings / conducting Postal Ballot process through voting by electronic means **("MCA Circulars")**, Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Circulars issued from time to time by SEBI (**"SEBI Circulars**") and Secretarial Standard (**"SS-2"**) issued by the Institute of Company Secretaries of India (ICSI) on General Meetings, that the resolutions set out below is proposed for approval of the shareholders of the Company through Postal Ballot by way of voting through electronic means **("remote e-voting")** only.

Pursuant to Section 102, 110 and other applicable provisions of the Act, the explanatory statements pertaining to the said resolution setting out the material facts and the reasons/rationale thereof along with the Industry Standards on "Minimum information to be provided for review of the Audit Committee and Shareholders for approval of Related Party Transactions (RPT)", is annexed to this Postal Ballot Notice dated 29th May, 2026 (**"Postal Ballot Notice"**) for your consideration and forms part of this Notice.

In accordance with the provisions of the aforesaid Circulars, shareholders can vote only through the remote e-voting process. Accordingly, the Company is pleased to offer remote e-voting facility to all its shareholders to cast their vote electronically. In this regard, the Company has engaged the services of Central Depository Services (India) Limited (CDSL) for the purpose of providing remote e-voting facility to all its members.

Shareholders are requested to read the instructions in the Notes under the section "Instructions relating to e-voting" in this Postal Ballot notice to cast their vote electronically. Shareholders are requested to cast their vote through the e-voting process not later than **Friday, 28th August, 2026** (**5.00 pm**) to be eligible for being considered, failing which it will be considered that no vote has been casted.

In accordance with the provisions of MCA Circulars, those shareholders who have not yet registered their e-mail addresses are requested to register the same by following the procedure set out in the notes to this Postal Ballot Notice.

HENCE, IN COMPLIANCE WITH THE REQUIREMENTS OF THE MCA CIRCULARS, HARD COPY OF POSTAL BALLOT NOTICE ALONG WITH POSTAL BALLOT FORMS AND PRE-PAID BUSINESS REPLY ENVELOPE WILL NOT BE SENT TO THE MEMBERS FOR THIS POSTAL BALLOT AND MEMBERS ARE REQUIRED TO COMMUNICATE THEIR ASSENT OR DISSENT THROUGH THE REMOTE E-VOTING SYSTEM ONLY.

The Board of Directors of the Company has appointed Mr. C. Sudhir Babu, (FCS No.7666) Practicing Company Secretary as the Scrutinizer pursuant to Rule 22(5) of the Companies (Management and Administration) Rules, 2014, for conducting the postal ballot /e-voting process in a fair and transparent manner. The Scrutinizer's decision on the validity of the Postal Ballot shall be final.

The Scrutinizer will submit his report, after completion of scrutiny, to the Managing Director or Company Secretary of the Company. The results shall be declared on **Monday, 31st August, 2026** and will be displayed on the Company's website and on the website of Central Depository Services (India) Limited ("CDSL") at (www.evotingindia.com) and will be communicated to Stock Exchanges.

The resolutions, if passed by the requisite majority, shall be deemed to have been passed on **Friday, 28th August, 2026** i.e., the last date specified for receipt of votes through e-voting process.

The shareholders are requested to consider and, if thought fit, pass the following resolutions:

<u>SPECIAL BUSINESS:</u>

1) Approval for reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director for a period of 5 (five) years.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 188, 196, 197, 198 and other applicable provisions, if any, read with Companies (Appointment and Qualifications of Directors) Rules, 2014, Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time) and under the provisions of the Articles of Association of the Company and pursuant to the recommendation of the Audit Committee, Nomination & Remuneration Committee and Board of Directors, the consent of the members of the Company be and is hereby accorded for reappointment of Mrs. Sudeepthi Gopineedi (DIN: 09102540), as Whole-time Director of the Company, for a further period of 5 (five) years commencing from 2nd September, 2026, on such terms and conditions as set out in the explanatory statement relating to this resolution.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to enter into an Agreement on behalf of the Company with Mrs. Sudeepthi Gopineedi on the terms and conditions set out in the Explanatory Statement annexed to this Notice.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts, deeds and things as may be necessary and to take all such steps as may be necessary, proper or expedient to give effect to this resolution."

2) Approval of overall Managerial Remuneration limits payable to Executive Directors pursuant to Regulation 17(6)(e) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution:**

"RESOLVED THAT pursuant to Regulation 17(6)(e)(ii) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and pursuant to the recommendation of Nomination and Remuneration Committee, Audit Committee and Board of Directors, the consent of the members of the Company be and is hereby accorded to the managerial remuneration payable to Executive Directors as set out in the explanatory statement relating to this resolution, which may exceed the limit of 5% (five percent) of the net profits of the Company in any year, computed in the manner laid down in Section 198 of the Companies Act, 2013:

RESOLVED FURTHER THAT where in any year, the Company has no profits or profits are inadequate, the overall annual managerial remuneration paid to the Executive Directors shall not exceed ₹5,00,00,000/- (Rupees Five Crores Only).

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts, deeds and things as may be necessary and to take all such steps as may be necessary, proper or expedient to give effect to this resolution."

3) Approval of material Related Party Transactions for the year 2026-27.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 188 and all other provisions, if any of the Companies Act, 2013 read with Rule 15 of the Companies (Meeting of Board and its Powers) Rules, 2014 and Regulation 23(4) read with Schedule XII of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, as amended from time to time and pursuant to the Company's policy on materiality of Related Party Transactions and dealing with Related Party Transactions and based on the approval / recommendation of the Audit Committee and Board of Directors, consent of the Members of the Company be and is hereby accorded to enter into / continue with the existing Related Party Transaction(s)(whether by way of an individual transaction or transactions taken together or series of transactions or otherwise) as set out in the Explanatory Statement with 'Related Parties' within the definition of Regulation 2(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which may exceed 10% of the annual consolidated turnover of the Company for the last year (i.e. 2025-26), on such terms and conditions as may be agreed between the Company and such related parties, in the ordinary course of business of the Company and at an arm's length basis.

RESOLVED FURTHER THAT all actions taken by the Board or any person so authorised by the Board, in connection with any matter referred to or contemplated in any of the foregoing resolution, be and are hereby approved, ratified and confirmed in all respects.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to negotiate, finalize, amend and revise the terms and conditions of the aforesaid transactions and execute such agreements, documents and letters thereof as may be necessary, from time to time and to do all such acts, deeds and things as may be necessary or expedient to give effect to this resolution."

4) Approval of material Related Party Transactions of the Material Subsidiary of the Company for the year 2026-27.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 188 and all other provisions, if any of the Companies Act, 2013 read with Rule 15 of the Companies (Meeting of Board and its Powers) Rules, 2014 and Regulation 23(4) read with Schedule XII of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, as amended from time to time and pursuant to the Company's policy on materiality of Related Party Transactions and dealing with Related Party Transactions and based on the approval / recommendation of the Audit Committee and Board of Directors, consent of the Members of the Company be and is hereby accorded to enter into / continue with the existing Related Party Transaction(s) by the material subsidiary of the Company (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise)as set out in the Explanatory Statement with 'Related Parties' within the definition of Regulation 2(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which may exceed 10% of the annual consolidated turnover of the Company for the last year (i.e. 2025-26) on such terms and conditions as may be agreed between the material subsidiary of the Company and such related parties, in the ordinary course of business of the Company and at an arm's length basis.

RESOLVED FURTHER THAT all actions taken by the Board or any person so authorised by the Board, in connection with any matter referred to or contemplated in any of the foregoing resolutions, be and are hereby approved, ratified and confirmed in all respects.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to negotiate, finalize, amend and revise the terms and conditions of the aforesaid transactions and execute such agreements, documents and letters thereof as may be necessary, from time to time and to do all such acts, deeds and things as may be necessary or expedient to give effect to this resolution."

By order of the Board
For Haleos Labs Limited
Formerly known as SMS Lifesciences India Limited

Trupti Ranjan Mohanty
Company Secretary
ICSI Memb. No. F13407

Date: 29.05.2026
Place: Hyderabad

NOTES:

1. An Explanatory Statement pursuant to Section 102 and 110 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014, setting out the material facts and reasons for the resolutions in respect of the businesses set out above is annexed hereto.

2. The Board of Directors of the Company in the Board meeting held on 29th May, 2026 has approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole Time Director, which needs to be approved by the shareholders within 90 days. As the General Meeting is not scheduled within the stipulated timeline, approval of the shareholders is sought by this Postal Ballot as per the provisions of the Companies Act, 2013 and rules made thereunder.

3. Any query in relation to the Resolutions proposed to be passed by this Postal Ballot may be addressed to Company Secretary and Compliance Officer at cs@haleoslabs.com

4. In compliance with the provisions of Section 108 and Section 110 and other applicable provisions of the Act read with the Management Rules and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is pleased to offer e-voting facility to all the Members of the Company. For this purpose, the **Company has engaged the services of CDSL for facilitating e-voting** to enable the Members to cast their votes electronically.

5. The Postal Ballot Notice is being sent only by email to all the Members, whose names appear on the Register of Members/List of Beneficial Owners as received from National Securities Depository Limited ('NSDL') and Central Depository Services (India) Limited ('CDSL') as on Friday, 24th July, 2026 **(the 'cut-off date')** and who have registered their email addresses in respect of electronic holdings with the Depository through the concerned Depository Participants and in respect of physical holdings with Company's Registrar and Share Transfer Agent **("RTA")** i.e. Aarthi Consultants Private Limited.

6. Members may note that the aforesaid Postal Ballot Notice has been uploaded on the website of the Company at www.haleoslabs.com. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

   The Postal Ballot Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility). Accordingly, members who have not registered their e-mail address may register their e-mail address by sending an email to Company (cs@haleoslabs.com) / RTA (info@aarthiconsultants.com) , along with their folio no./DP ID client ID and valid email address for registration.

7. The voting rights of the Members shall be reckoned in proportion to the equity shares held by them on the cut-off date. Only those Members holding shares either in physical form or dematerialized form as on the Cutoff date will be entitled to cast their votes by remote e-voting. A person who is not a Member as on the Cut-off date should treat this Postal Ballot Notice for information purposes only.

8. Resolutions, if passed by the Members through Postal Ballot is deemed to have been duly passed on the last date specified for the remote e-voting i.e., on **Friday, 28th August, 2026** and shall be deemed to have been passed at a general meeting of Members convened on that behalf.

9. A member cannot exercise his vote by proxy on a Postal Ballot.

10. SEBI has mandated the submission of PAN, KYC details and nomination by holders of physical securities vide its circulars dated 3rd November, 2021, 14th December, 2021, 16th March, 2023, 17th November, 2023 and 7th May, 2024. It is also mandatory to link PAN with Aadhaar. Shareholders are requested to submit their PAN, KYC and nomination details to the Company's RTA at info@aarthiconsultants.com

    Members holding shares in electronic form are therefore, requested to submit their PAN to their depository participant(s). In case a holder of physical securities fails to furnish these details or link their PAN with Aadhaar, RTA is obligated to freeze such folios. The securities in the frozen folios shall be eligible to receive payments (including dividend) and lodge grievances only after furnishing the complete documents.

INSTRUCTIONS FOR VOTING THROUGH ELECTRONIC MEANS:

The procedure and instructions for voting through electronic means are as follows:

i) In compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Section 108, 110 and other applicable provisions of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), the Company is providing the facility of e-voting to its members in respect of the business to be transacted through Postal Ballot.

ii) Company has appointed Central Depository Services (India) Limited ("CDSL") as the authorised e-Voting agency for facilitating voting through electronic means.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, CDSL, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai – 400013.

iii) Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on Friday, 24th July, 2026 **("Cut-off Date"),** shall be entitled to avail the facility of e-voting.

iv) The voting period begins on **Thursday, 30th July, 2026 at 09.00 am and will end on Friday, 28th August, 2026 at 05.00 pm**. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter. Once the vote on the resolutions is cast by member, he/she shall not be allowed to change it subsequently or cast the vote again.

v) In terms of SEBI Circular No. SEBI/HO/CFD/ CMD/CIR/P/2020/242 dated 9th December, 2020 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions.

Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email ID in their demat account in order to access e-Voting facility.

Pursuant to aforesaid SEBI Circular, login method for remote e-voting for Individual shareholders holding securities in various modes with CDSL / NSDL is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user ID and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by the Company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting the vote during the remote e-Voting period. 3. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. 4. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration

Type of shareholders	Login Method
	5. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page or click on https://evoting.cdslindia.com/Evoting/EvotingLogin. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with NSDL	1. If you are already registered for the NSDL IDeAS facility, please visit the e-Services website of NSDL. Open a web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting'' under e-Voting services and you will be able to see the e-Voting page. Click on Company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period. 2. If the user is not registered for IDeAS e-Services, the option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp . 3. Visit the e-Voting website of NSDL. Open a web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to the NSDL Depository site wherein you can see the e-Voting page. Click on Company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on the e-Voting option, you will be redirected to the NSDL/CDSL Depository site after successful authentication, wherein you can see the e-Voting feature. Click on Company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned websites.

HELPDESK FOR INDIVIDUAL SHAREHOLDERS HOLDING SECURITIES IN DEMAT MODE FOR ANY TECHNICAL ISSUES RELATED TO LOGIN THROUGH DEPOSITORY I.E. CDSL AND NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with **CDSL**	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with **NSDL**	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

vi) **Login method for e-Voting for Physical shareholders and shareholders other than individual holding in Demat form.**

1) The shareholders should log on to the e-voting website www.evotingindia.com.

2) Click on the "Shareholders" module.

3) Now enter your User ID

a. For CDSL: 16 digits beneficiary ID,

b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,

c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

4) Next enter the Image Verification as displayed and Click on Login.

5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any Company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

For Physical shareholders and other than individual shareholders holding shares in Demat.	
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the Company records in order to login. • If both the details are not recorded with the depository or Company, please enter the member ID / folio number in the Bank details field.

vii) After entering these details appropriately, click on the **"SUBMIT"** tab.

viii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach the 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password can also be used by the demat holders for voting for resolutions of any other Company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

ix) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

x) Click on the **EVSN** for the relevant <Haleos Labs Limited> on which you choose to vote.

xi) On the voting page, you will see **“RESOLUTION DESCRIPTION”** and against the same the option **“YES/NO”** for voting. Select the option “YES or NO” as desired. The option “YES” implies that you assent to the Resolution and option “NO” implies that you dissent to the Resolution.

xii) Click on the **“RESOLUTION FILE LINK”** if you wish to view the entire Resolution details.

xiii) After selecting the resolution, you have decided to vote on, click on **“SUBMIT”.** A confirmation box will be displayed. If you wish to confirm your vote, click on **“OK”,** else to change your vote, click on **“CANCEL”** and accordingly modify your vote.

xiv) Once you **“CONFIRM”** your vote on the resolution, you will not be allowed to modify your vote.

xv) You can also take a print of the votes cast by clicking on **“Click here to print”** option on the Voting page.

xvi) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

xvii) Additional Facility for Non – Individual Shareholders and Custodians –for Voting only.

a) Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.

b) A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.

c) After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.

d) The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.

e) A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

f) Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer with a copy marked to the Company, if they have voted from individual tab & not uploaded the same in the CDSL e-voting system for the scrutinizer to verify the same.

We urge Members to support our commitment to environmental protection by choosing to receive the Company’s communication through email.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

a) **For Physical shareholders-** please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to cs@haleoslabs.com and info@aarthiconsultants.com .

b) **For Demat shareholders-** Please update your email id & mobile no. with your respective Depository Participant (DP)

c) **For Individual Demat shareholders –** Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting.

IN CASE OF ANY QUERY/GRIEVANCE IN CONNECTION WITH THE POSTAL BALLOT INCLUDING REMOTE E-VOTING, MEMBERS MAY CONTACT THE BELOW:

Company	:	**Haleos Labs Limited** Phone: 40-6628 8888 / 9861129909 Email: info@haleoslabs.com / cs@haleoslabs.com
Registrar & Transfer Agent	:	**Aarthi Consultants Private Limited** Phone: 040-27638777/ 27642217 / 27634445 Email: info@aarthiconsultants.com
e-Voting Agency	:	**Central Depository Services (India) Limited** Phone : 022- 23058738 and 022-23058542/43 E-mail: helpdesk.evoting@cdslindia.com
Scrutinizer	:	**Mr. C. Sudhir Babu,** Practicing Company Secretary Phone: 7981191458/ 9493676368 Email : csbassociates27@gmail.com

ANNEXURE TO NOTICE:

Explanatory Statement pursuant to Section 102 of the Companies Act, 2013

Item#01: Reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director for a period of 5 (five) years.

Mrs. Sudeepthi Gopineedi (DIN: 09102540) was appointed as a Whole-Time Director of the Company at the 15th Annual General Meeting of the Company held on 30th September 2021, for a period of 5 (five) years effective from 2nd September, 2021. Accordingly, the current tenure of Mrs. Sudeepthi Gopineedi will get completed on 1st September, 2026.

Considering her experience and significant contributions to the Company, the Board of Directors of the Company at its meeting held on 29th May, 2026, on recommendation of Nomination and Remuneration Committee and Audit Committee, approved the re-appointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director for a further period of 5 (five) years, commencing from 2nd September 2026, subject to approval of shareholders.

In terms of Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company shall ensure that approval of members for appointment of a person on the Board of Directors is taken at the next general meeting or within a time period of three months from the date of appointment, whichever is earlier.

In view of the above, approval of the members is sought by Postal Ballot for re-appointment of Mrs. Sudeepthi Gopineedi as "Whole Time Director" of the Company.

Brief profile:

Mrs. Sudeepthi Gopineedi is a postgraduate from Birla Institute of Technology and Science, Pilani with qualifications in Chemistry and Computer Science and has earned multiple academic distinctions and leadership accolades. Prior to joining Haleos Labs, she worked with reputed multinational organisations Including Amazon, Oracle, The World Bank and Blue Cross Blue Shield Association, gaining extensive international exposure.

During her association with the Company, she has led key quality and operational initiatives, including the successful completion of Regulatory audits and several customer audits, contributing significantly to the Company's growth and compliance standards.

Declarations:

Mrs. Sudeepthi Gopineedi satisfies all conditions set out in Part-I of Schedule V to the Companies Act, 2013 as also conditions set out under Section 196(3) of the Companies Act, 2013 for her re-appointment. She is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013. The Company has received consent letter from Mrs. Sudeepthi Gopineedi in relation to her re-appointment.

Rationale for Reappointment:

- Mrs. Sudeepthi has been instrumental in driving key business initiatives and contributing to the Company's sustained growth through her strategic vision and proactive leadership.
- She has played a significant role in strengthening the Company's operational capabilities, fostering innovation and supporting the successful execution of various strategic and business development initiatives.
- She has successfully led critical regulatory inspections and customer audits, reinforcing the Company's commitment to global quality standards and enhancing its credibility with regulators and customers across international markets.
- Her continued association with the Company will ensure stability in leadership and facilitate the seamless implementation of the Company's long-term growth strategy, expansion plans and Company' objectives.
- She possesses a deep understanding of the Company's business, industry dynamics, and evolving market environment, enabling her to effectively guide the management team in addressing future opportunities and challenges.

The Nomination & Remuneration Committee and the Board are of the view that Mrs. Sudeepthi Gopineedi possesses the requisite skills and capabilities. Considering the skills, experience and expertise, the Nomination & Remuneration Committee and the Board considers that this association would be of immense benefit to the Company.

Terms and Conditions of the reappointment:

a) Period of reappointment:

Reappointment is for a period of 5 (five) years w.e.f. 2nd September, 2026.

(Liable to retire by rotation)

b) Remuneration / Salary:

Monthly remuneration in the range of ₹2.50 lakhs to ₹4.00 lakhs, as may be determined from time to time by the Nomination and Remuneration Committee and the Board of Directors.

c) Perquisites:

In addition to above, she shall also be entitled to perquisites together with reimbursement of actual expenses for utilities such as gas, electricity, water, furnishings, air-conditioning and repairs, all of which may be hired or owned; medical reimbursement; club fees, foreign travel and leave travel concession for herself and her family; medical insurance and such other perquisites and allowances in accordance with the rules of the Company or as may be agreed by the Board of Directors.

d) Commission:

She shall also be entitled to a Commission on the profit of the Company as may be decided by the Board of Directors from time to time.

e) Annual Bonus:

She shall also be entitled to an Annual Bonus based on the performance of the Company and subject to the approval of the Board of Directors.

f) Others Terms & Conditions:

- ❑ For the purposes of calculating the above overall ceiling, value of perquisites & allowances shall be as per Income Tax Rules, wherever applicable; in the absence of any such rules, perquisites and allowances shall be evaluated at actual cost or hire charges.
- ❑ She shall be entitled to travel in India or aboard, boarding and lodging including attendants during business trips and provision for use of the Company's car for official duties and telephone / Internet facility at residence shall not be included in computation of perquisites for the purpose of calculating the said ceiling.

- Company's contribution to Provident Fund and Superannuation or Annuity Fund, to the extent that these either singularly or together are not taxable under the Income Tax Act.
- She is also entitled to Gratuity payable as per the rules of the Company and encashment of leave at the end of the tenure.
- The terms and conditions of the said appointment may be altered and varied from time to time by the Board as it may, in its discretion, deem fit, within the maximum amount payable to her in accordance with Schedule V of the Companies Act, 2013 or any amendments thereto made hereinafter in this regard.
- All these shall not be included in the computation of perquisites for the purpose of calculating the ceiling(s) aforesaid.

Note –

1) All these shall not be included in the computation of perquisites for the purpose of calculating the ceilings aforesaid and if at any time Mrs. Sudeepthi Gopineedi ceases to be a Director of the Company for any reason whatsoever, she shall also cease to be Whole-time Director of the Company.

2) The aforesaid remuneration is within the limits prescribed under Regulation 23 read with Schedule XII of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of Director seeking Re-appointment pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings (SS-2):

Name of the Director	Mrs. Sudeepthi Gopineedi
Director Identification Number (DIN)	09102540
Date of Birth	02.03.1987
Nationality	Indian
Date of first appointment on Board	02.09.2021
Qualification	▪ Post graduate from BITS-Pilani campus, with a Masters in Chemistry ▪ Bachelors in Computer Science Engineering
Nature of expertise in specific functional areas	She joined the Company in 2018 as General Manager – Operations and has since played a pivotal role in strengthening the Company's quality and operational functions. Prior to joining the Company, she worked with leading multinational technology companies, including Amazon and Oracle, in India. During her 7 years stay in the United States, she gained valuable international experience with globally renowned organizations such as "The World Bank" and "the Blue Cross Blue Shield Association", broadening her expertise in business operations, quality systems and business management. During her association with the Company, she has spearheaded several initiatives to strengthen the Quality Management System and streamline operational processes. Under her supervision, the Company successfully completed its USFDA inspection, along with several other regulatory and customer audits, significantly enhancing the Company's quality standards, regulatory compliance and global reputation.
Names of other listed entities in which the person also holds the Directorship and the membership of Committees of the Board	Nil

<table>
<tr><td>Justification for reappointment</td><td>She fulfils the conditions specified in the Companies Act, 2013, the Companies (Appointment and Qualifications of Directors) Rules, 2014 and SEBI (Listing Obligations and Disclose Requirements) for her re-appointment as a Whole-time Director of the Company and possesses appropriate skills, education, experience and knowledge.

Brief on her contribution to the growth of the Company is mentioned in the explanatory statement.

In this regard, Nomination & Remuneration Committee and Board has approved and recommended to the shareholders for the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a further period of 5 years.</td></tr>
<tr><td>No. of Board Meetings attended during the year 2025-26</td><td>4 out of 4</td></tr>
<tr><td>Directorships /chairmanship held in other public Companies</td><td>Nil</td></tr>
<tr><td>Relationship between Directors Inter-se</td><td>Daughter of Mr. TVVSN Murthy, Managing Director and Sibling of Mr. TV Praveen, Executive Director</td></tr>
<tr><td>Shareholding</td><td>1,99,494 (6.60%)</td></tr>
<tr><td>Remuneration drawn in the last year (FY 2025-26)</td><td><table><tr><th>Salary</th><th>Perks</th><th>Total</th><th>%age of net profit</th></tr><tr><td>₹24,00,000</td><td>₹2,76,947</td><td>₹26,76,947</td><td>0.94%</td></tr></table></td></tr>
<tr><td>Remuneration proposed to be paid</td><td>As mentioned in the explanatory statement</td></tr>
<tr><td>Terms and conditions of appointment / Re-appointment along with details of remuneration sought to be paid and remuneration last drawn by such person.</td><td>Terms and conditions as mentioned in the explanatory statement and as per the policy of the Company as displayed on the Company's website.</td></tr>
</table>

The above may be treated as an abstract and written memorandum setting out the terms of appointment and remuneration of Mrs. Sudeepthi Gopineedi as a Whole-time Director under Section 190 of the Companies Act, 2013.

In compliance with circular no. NSE/CML/2018/02 issued by National Stock Exchange of India Limited and circular No. LIST/COMP/14/2018-19 issued by BSE Limited dated 20th June, 2018 and based on the available information, the Board hereby affirm that Mrs. Sudeepthi Gopineedi is not debarred from holding the office of Director by virtue of any SEBI order or any other authorities.

The Board, based on the recommendation made by the Audit Committee, Nomination and Remuneration Committee, recommends the resolution set forth in Item No. 1 of the notice for approval of the members by passing a **Special Resolution**.

Mr. TVVSN Murthy and Mr. T.V. Praveen are interested in the resolution set out at Item No. 1 of the Notice with regard to reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director of the Company.

Save and except the above, no other Director, Key Managerial Personnel, or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the said resolution.

Item#02: Overall Remuneration Payable to Executive Directors.

Managerial Remuneration to Executive Directors in excess of below mentioned threshold shall be paid only with the approval of members by passing Special Resolution pursuant to Regulation 17(6)(e) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- ❑ Annual remuneration payable individually exceeding 2.5% of the net profit or 5 (five) crores, whichever is higher.
- ❑ **Annual remuneration in aggregate payable exceeds 5% of the net profits.**

In this regard, the Company has obtained the approval of members of the Company vide Postal Ballot dated 30th July, 2025, in order to pay the following aggregate managerial remuneration to the Executive Directors of the Company:

Name of Executive Director	**Monthly Remuneration [₹]	**Annual remuneration [₹]
Mr. TVVSN Murthy	16,50,000	1,98,00,000
Mr. TV Praveen	9,00,000	1,08,00,000
Mrs. Sudeepthi Gopineedi	2,00,000	24,00,000
Total	**27,50,000**	**3,30,00,000**

**** plus perquisites.**

However, as per the second proviso of Regulation 17(6)(e) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the approval of the members shall be valid only till the expiry of the term of such Executive Director. Since the tenure of Mrs. Sudeepthi Gopineedi as Whole-time Director is set to conclude on 1st September, 2026, her reappointment is proposed for a further period of 5 (five) years.

Hence, fresh approval of the members is required to pay the aggregate annual managerial remuneration payable to the Executive Directors, as it may exceed the prescribed limit of 5% (five percent) of the net profits of the Company, calculated in accordance with the provisions of Section 198 of the Companies Act, 2013.

Accordingly, pursuant to Regulation 17(6)(e)(ii) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors, based on the recommendation of the Nomination & Remuneration Committee, at its meeting held on 29th May, 2026, considered and approved the proposal to increase the aggregate managerial remuneration payable to the Executive Directors of the Company, *as mentioned below,* in respect of any financial year, even if such remuneration exceeds 5% (five percent) of the net profits of the Company, computed in accordance with Section 198 of the Companies Act, 2013, subject to the approval of the members of the Company by Postal Ballot.

Name of Executive Director	**Maximum Monthly Remuneration [₹]	** Maximum Annual remuneration [₹]
Mr. TVVSN Murthy	16,50,000	1,98,00,000
Mr. TV Praveen	9,00,000	1,08,00,000
Mrs. Sudeepthi Gopineedi	4,00,000	48,00,000
Total	**29,50,000**	**3,54,00,000**

**** Plus perquisites**

The Board recommends the resolution set forth in Item No. 2 of the notice for approval of the members by passing a **Special Resolution**.

Mr. TVVSN Murthy, Mr. T.V. Praveen and Mrs. Sudeepthi Gopineedi are interested in the resolution set out at Item No. 2 of the Notice with regard to increase of managerial remuneration to Executive Directors of the Company.

Save and except the above, no other Director, Key Managerial Personnel, or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the said resolution.

Item#03: Material Related Party Transactions of the Company for the year 2026-27:

The Company is engaged in the business of manufacturing, research, development and commercialization of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates and bulk drugs. The Company caters to both domestic and international markets through its state-of-the-art manufacturing facilities and its subsidiary.

The annual consolidated turnover of the Company for the year 2025-26 was ₹333.79 Crores.

Pursuant to the provisions of Section 188 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, approval of the Board of Directors and, where applicable, the prior approval of the Members by way of an Ordinary Resolution is required for specified Related Party Transactions exceeding the prescribed thresholds. However, the said provisions are not applicable to transactions entered into in the ordinary course of business and on an arm's length basis.

Notwithstanding the above, pursuant to Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, prior approval of the Members is required for all Material Related Party Transactions, irrespective of whether such transactions are in the ordinary course of business and on an arm's length basis.

In terms of Regulation 23 read with Schedule XII of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Related Party Transaction shall be considered material if the value of the transaction(s), whether entered into individually or taken together with previous transactions during a year, exceeds 10% of the annual consolidated turnover of the Company as per its last audited financial statements, in the case of companies having an annual consolidated turnover of up to ₹20,000 Crores.

Based on the audited consolidated financial statements of the Company for the year 2025-26, the materiality threshold works out to ₹33.37 Crores. Accordingly, approval of the Members by way of an Ordinary Resolution is being sought for the proposed Material Related Party Transactions.

Considering the nature of the Company's business, it regularly enters into operational and business transactions with its subsidiary and other related parties to facilitate efficient business operations, procurement, manufacturing, sale of products and other business requirements.

All such transactions are proposed to be undertaken in the ordinary course of business and on an arm's length basis. The values of the related party transactions set out in the tables below and are inclusive of applicable taxes and duties.

Following shall be considered as "Material Related Party Transactions" of the Company for the year 2026-27, based on the annual audited consolidated turnover of the Company for the previous year (i.e. 2025-26):

[₹ in Crores]

Name of related party	Nature of transaction	Threshold limit**	Aggregate proposed limits
Mahi Drugs Private Limited[1]	Sale & Purchase of Goods & Services, rent and business advances	33.37	85.10
Purogene Labs Private Limited[2]	Sale & Purchase of Goods & Services, rent and business advances	33.37	50.60

1- Subsidiary Company | 2 - Directors have significant influence

****10% of consolidated turnover (i.e. ₹333.79 Crs) of the Company for the year 2025-26.**

The amended Regulation 2(1)(zc) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has also enhanced the definition of Related Party Transactions which now includes a transaction involving a transfer of resources, services or obligations between a <u>listed entity</u> or any of its subsidiaries on <u>one hand</u> and a <u>related party of the listed entity</u> or any of its subsidiaries on the <u>other hand</u>, regardless of whether a price is charged or not.

Audit Committee has been provided with the relevant details about the proposed Related Party Transactions including rationale, material terms and justification for the same pursuant to Paragraph 4 under Part B of Section III-B of the SEBI master circular dated 30th January, 2026.

In this regard, the Audit Committee has also confirmed that the relevant disclosures for decision-making of the Committee were placed before it and while approving the same, the Committee has determined that the transaction is not prejudicial to the interest of the Company or its shareholders and is in the best interest of the Company and also reviewed the certificate provided by the Managing Director and Chief Financial Officer in this regard.

The Board of Directors based on recommendation of the Audit Committee at their meeting held on 11th February, 2026, have accorded approval to enter into aforesaid material Related Party Transactions with 'Related Parties' within the definition of Regulation 2(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (whether individual transaction or transactions taken together or series of transactions or otherwise) for the year 2026-27.

Minimum Information:

SEBI vide its circular no. SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/93 dated 26th June, 2025 read with FAQ dated 4th September, 2025 has introduced the Industry Standards on "Minimum information to be provided for review of the Audit Committee and Shareholders for approval of Related Party Transaction" ("**RPT Industry Standards**") to facilitate uniform approach and assist the Company in complying with the provisions of Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Minimum information required pursuant to RPT Industry Standards is provided separately in Annexure A.

The Board and Audit Committee of the Company have considered the aforesaid information and has accorded its prior approval to the transaction subject to approval of the Members through Postal Ballot

The aforesaid estimated value of the proposed transactions may exceed the material threshold limits as prescribed under Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the Actual value of the transactions may vary depending upon the business requirements.

Furthermore, the value of Related Party Transactions with aforesaid Related Parties for the period commencing from 1st April, 2026 to the date of this Notice has not exceeded the material thresholds and the Company will ensure that the same does not exceed the aforesaid threshold upto the date of declaration of results of this Postal Ballot.

The aforesaid transactions shall also be reviewed/ monitored on quarterly basis by the Audit Committee of the Company and shall at all time remain within the aforesaid limits. It is further clarified that while the sub-limits of individual transactions (i.e. sale or purchase of Goods or services) may be utilized interchangeably based on business requirements, the aggregate value of transactions shall at all times remain within the overall limits as approved by the shareholders.

However, in case of any subsequent material modifications as defined in the Company's policy on materiality of Related Party Transactions and dealing with Related Party Transactions, shall be placed before the members for approval, in terms of Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board, based on the recommendation made by the Audit Committee, recommends the resolution set forth in item no.3 of the notice for approval of the members by passing an **Ordinary Resolution**.

All entities falling under the definition of related party of the Company shall abstain from voting irrespective of whether the individual/entity is party to the particular transaction or not.

Mr. TVVSN Murthy, Mr. T.V. Praveen and Mrs. Sudeepthi Gopineedi are interested in the resolution as set out at Item No. 3 of the Notice with regard to approval of proposed material Related Party Transactions for the year 2026-27.

Save and except the above, no other Director, Key Managerial Personnel, or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the said resolution.

Item#04: Material Related Party Transactions of the Subsidiary of the Company for the year 2026-27:

The Company and its subsidiary both are engaged in the business of manufacturing, research, development and commercialization of Active Pharmaceutical Ingredients (APIs) and its inter intermediates. The Company caters to both domestic and international markets through its state-of-the-art manufacturing facilities and its subsidiary.

The annual consolidated turnover of the Company for the year 2025-26 was ₹333.79 Crores and Standalone consolidated turnover of the Subsidiary Company was ₹59.02 Crores.

Pursuant to the provisions of Section 188 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, approval of the Board of Directors and, wherever applicable, the prior approval of the Members by way of an Ordinary Resolution is required for specified Related Party Transactions exceeding the prescribed thresholds.

However, the said provisions are not applicable to transactions entered into in the ordinary course of business and on an arm's length basis.

Notwithstanding the above, pursuant to Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, prior approval of the Members is required for all Material Related Party Transactions, irrespective of whether such transactions are in the ordinary course of business and on an arm's length basis.

In terms of Regulation 23 read with Schedule XII of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Related Party Transaction shall be considered material if the value of the transaction(s), whether entered into individually or taken together with previous transactions during a year, exceeds 10% of the annual consolidated turnover of the Company as per its last audited financial statements, in the case of companies having an annual consolidated turnover of up to ₹20,000 Crores.

Based on the audited consolidated financial statements of the Company for the year 2025-26, the materiality threshold works out to ₹33.37 Crores. Accordingly, the approval of the Members by way of an Ordinary Resolution is being sought for the proposed Material Related Party Transactions.

Considering the nature of the subsidiary's business, it regularly enters into operational and business transactions with its related parties to facilitate efficient business operations, procurement, manufacturing, sale of products and other business requirements.

All such transactions are proposed to be undertaken in the ordinary course of business and on an arm's length basis. The values of the related party transactions set out in the tables below and are inclusive of applicable taxes and duties.

Following shall be considered as "Material Related Party Transactions" of the Company pertaining to the Material Subsidiary for the year 2026-27, based on the annual audited consolidated turnover of the Company for the previous year (i.e. 2025-26):

[₹ in Crores]

Name of related party	Nature of transaction	Threshold limit**	Aggregate proposed limits
ChemWerth Inc, USA[1]	Sale & Purchase of Goods & Services, Business advance	33.37	55.00

1- Other related parties

****10% of consolidated turnover (i.e. ₹333.79 Crs) of the Company for the year 2025-26.**

To avoid duplication of approvals, the corresponding (contra) Related Party Transactions between the subsidiary and the Company, already covered under Agenda Item No. 3, have not been placed separately for approval under Agenda Item No. 4.

The amended Regulation 2(1)(zc) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has also enhanced the definition of Related Party Transactions which now includes a transaction involving a transfer of resources, services or obligations <u>between</u> a listed entity or any of <u>its subsidiaries on one hand</u> and a r<u>elated party</u> of the listed entity or any of <u>its subsidiaries on the other hand</u>, regardless of whether a price is charged or not.

Audit Committee has been provided with the relevant details about the proposed Related Party Transactions including rationale, material terms and justification for the same pursuant to Paragraph 4 under Part B of Section III-B of the SEBI master circular dated 30th January, 2026.

In this regard, the Audit Committee has also confirmed that the relevant disclosures for decision-making of the Committee were placed before it and while approving the same, the Committee has determined that the transaction is not prejudicial to the interest of the Company or its shareholders and is in the best interest of the Company and also reviewed the certificate provided by the Managing Director and Chief Financial Officer in this regard.

The Board of Directors based on recommendation of the Audit Committee at their meeting held on 11th February, 2026, have accorded approval to enter into aforesaid material Related Party Transactions pertaining to Mahi Drugs Private Limited (Material Subsidiary) with 'Related Parties' within the definition of Regulation 2(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (whether individual transaction or transactions taken together or series of transactions or otherwise) for the year 2026-27.

Minimum Information:

SEBI vide its circular no. SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/93 dated 26th June, 2025 read with FAQ dated 4th September, 2025 has introduced the Industry Standards on "Minimum information to be provided for review of the Audit Committee and Shareholders for approval of Related Party Transaction" ("**RPT Industry Standards**") to facilitate uniform approach and assist the Company in complying with the provisions of Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Minimum information required pursuant to RPT Industry Standards is provided separately in Annexure B.

The Board and Audit Committee of the Company have considered the aforesaid information's and has accorded its prior approval to the transaction subject to approval of the Members through Postal Ballot

The aforesaid estimated value of the proposed transactions may exceed the material threshold limits as prescribed under Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the Actual value of the transactions may vary depending upon the business requirements.

Furthermore, the value of Related Party Transactions with aforesaid Related Parties for the period commencing from 1st April, 2026 to the date of this Notice has not exceeded the material thresholds and the Subsidiary Company will ensure that the same does not exceed the aforesaid threshold upto the date of declaration of results of this Postal Ballot.

The aforesaid transactions shall also be reviewed/ monitored on quarterly basis by the Audit Committee of the Company and Board of the Subsidiary Company and shall at all time remain within the aforesaid limits. It is further clarified that while the sub-limits of individual transactions (i.e. sale or purchase of Goods or services) may be utilized interchangeably based on business requirements, the aggregate value of transactions shall at all times remain within the overall limits as approved by the shareholders.

However, in case of any subsequent material modifications as defined in the Company's policy on materiality of Related Party Transactions and dealing with Related Party Transactions, shall be placed before the members for approval, in terms of Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board, based on the recommendation made by the Audit Committee, recommends the resolution set forth in item no. 4 of the notice for approval of the members by passing **an Ordinary Resolution**.

All entities falling under the definition of related party of the Company shall abstain from voting irrespective of whether the individual/entity is party to the particular transaction or not.

Mr. TVVSN Murthy, Mr. T.V. Praveen and Mrs. Sudeepthi Gopineedi are interested in the resolution as set out at Item No. 4 of the Notice with regard to approval of proposed material Related Party Transactions for the year 2026-27.

Save and except the above, no other Director, Key Managerial Personnel, or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the said resolution.

By order of the Board
For Haleos Labs Limited
Formerly known as SMS Lifesciences India Limited

Date: 29.05.2026
Place: Hyderabad

Trupti Ranjan Mohanty
Company Secretary
ICSI Memb. No. F13407

Registered office:
Plot No.19-III, Road No.71, Jubilee Hills,
Opp. Bharatiya Vidya Bhavan Public School, Hyderabad – 500096.

Annexure A

Disclosure in accordance with SEBI Circular dated June 26, 2025, on the Industry Standards on "Minimum Information to be provided to the Audit Committee and Shareholders for Approval of Related Party Transactions (RPTs)" ("RPT Industry Standards" or "Standards")

Part A

Minimum information of the proposed RPT, applicable to all RPTs

Details of the material Related Party Transactions with Mahi Drugs Private Limited and Purogene Labs Private Limited, being a related parties of the Company

A(1). Basic details of the related party

S. No.	Particulars of the information	Information provided by the management	
1	Name of the related party	Mahi Drugs Private Limited ("MDPL")	Purogene Labs Private Limited ("PLPL")
2	Country of incorporation of the related party	India	India
3	Nature of business of the related party	Manufacture of APIs and its intermediaries.	Manufacturing of intermediates of Active Pharma Ingredients (APIs)

A(2). Relationship and ownership of the related party

S. No.	Particulars of the information	Information provided by the management	
		Mahi Drugs Private Limited ("MDPL)	**Purogene Labs Private Limited ("PLPL")**
1	Relationship between the Company and the related party – including nature of its concern (financial or otherwise) and the following:	Subsidiary Company (60% stake)	Promoter Group of the Company hold and control 100% of the equity share capital of PLPL and are in a position to exercise control over its affairs. Accordingly, PLPL qualifies as a related party of the Company in terms of the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
	● Shareholding of the Company, whether direct or indirect, in the related party.	60%	Nil
	● Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the Company.	Not applicable	Not applicable
	● Shareholding of the related party, whether direct or indirect, in the Company	Nil	Nil

(Contd.)

A(3). Details of previous transactions with the related party

S. No.	Particulars of the information	Information provided by the management: Mahi Drugs Private Limited ("MDPL)	Information provided by the management: Purogene Labs Private Limited ("PLPL")
1	Total amount of all the transactions undertaken by the Company with the related party during the last financial year.	**Transactions during the year 2025-26:** **Sl.No. Nature of transaction ₹ in lakhs** 1) Purchase of Goods 2,623.61 2) Sale of Goods 483.05 3) Lease rent received 6.37 4) Issued Corporate Guarantee 2,000.00 **Total 5,113.03**	**Transactions during the year 2025-26:** **Sl.No. Nature of transaction ₹ in lakhs** 1) Purchase of Goods 382.82 2) Sale of Goods 321.61 3) Purchase of Service 1,693.42 4) Lease rent received 4.25 **Total 2,402.10**
2	Total amount of all the transactions undertaken by the Company with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Not Applicable	
3	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the Company during the last financial year.	No such default	No such default

A(4). Amount of the proposed transaction(s)

S. No.	Particulars of the information	Information provided by the management: Mahi Drugs Private Limited ("MDPL)	Information provided by the management: Purogene Labs Private Limited ("PLPL")
1	Amount of the proposed transaction being placed for approval in the meeting of the Audit Committee.	**Sl No. Nature of transaction ₹ in lakhs** 1) Purchase of Goods 4,000 2) Sale of Goods 1,000 3) Purchase of services 500 4) Sale of Services 1,000 5) Trade advance payable** 2,000 6) Lease rent receipt 10 **Total 8,510**	**Sl No. Nature of transaction ₹ in lakhs** 1) Purchase of Goods 1,000 2) Sale of Goods 1,000 3) Purchase of services 2,000 4) Sale of Services 50 5) Trade advance payable** 1,000 6) Lease rent receipt 10 **Total 5,060**
2	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes, the aforesaid proposed transaction shall qualify as "Material RPT" as per the Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.	

(Contd.)

S. No.	Particulars of the information	Information provided by the management	
		Mahi Drugs Private Limited ("MDPL")	Purogene Labs Private Limited ("PLPL")
3	Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year	Annual Consolidated Turnover of the Company - **₹33,379.45 lakhs** Value of the proposed transactions – **₹8,510 lakhs** Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year –25.50%	Annual Consolidated Turnover of the Company - **₹33,379.45 lakhs** Value of the proposed transactions – **₹5,060 lakhs** Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year –15.16%
4	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year	Not applicable	Not applicable
5	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	Annual Standalone Turnover of MDPL - **₹5,902.01 lakhs** Value of the proposed transactions – **₹8,510 lakhs** Value of the proposed transactions as a percentage of MDPL's annual standalone turnover for the immediately preceding financial year **– 144.19%**	Provsional Annual Standalone Turnover of PLPL for the year 2025-26- **₹3,513.48 lakhs** Value of the proposed transactions – **₹5,060 lakhs** **Value of the proposed transactions as a percentage of PLPL's annual turnover for the last audited financials – 134.06%
6	Financial performance of the related party for the immediately preceding financial year: Explanations: The above information is to be given on standalone basis. If standalone is not available, provide on consolidated basis.	Financial performance of MDPL for the year 2025-26: Turnover - **₹5,902.01 lakhs** PAT - **₹122.08 lakhs** Net worth - **₹4,002.07 lakhs**	Provsional Financial performance of PLPL for the year 2025-26: Turnover - **₹3,513.48 lakhs** PAT - **₹506.55 lakhs** Net worth - **₹1,961.44 lakhs**

A(5). Basic details of the proposed transaction

S. No.	Particulars of the information	Information provided by the management	
		Mahi Drugs Private Limited ("MDPL")	Purogene Labs Private Limited ("PLPL")
1	Specific type of the proposed transaction	As mentioned in point no. A.4.1	
2	Details of each type of the proposed transaction	The transaction involves Sale & Purchase of goods, availing & rendering of Services and renting of property, including Trade advance. The maximum annual value of the proposed transactions is estimated based on the Company's current transactions and future business projections.	
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	Proposed transactions are recurring in nature. However, the approval of the shareholders is being sought for entering into Related Party Transactions for the year 2026-27.	

(Contd.)

<table>
<tr><th rowspan="2">S. No.</th><th rowspan="2">Particulars of the information</th><th colspan="2">Information provided by the management</th></tr>
<tr><th>Mahi Drugs Private Limited (“MDPL)</th><th>Purogene Labs Private Limited (“PLPL”)</th></tr>
<tr><td>4</td><td>Whether omnibus approval is being sought?</td><td colspan="2">No</td></tr>
<tr><td>5</td><td>Value of the proposed transaction during a financial year

If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise</td><td>As mentioned in point no. A.4.1.

Not applicable.</td><td>As mentioned in point no. A.4.1.

Not applicable.</td></tr>
<tr><td>6</td><td>Justification as to why the RPTs proposed to be entered into are in the interest of the Company.</td><td colspan="2">The proposed Related Party Transactions are in the best interest of the Company and are intended to furtherance of its core business objectives. These arrangements aim to achieve operational synergies, reduce costs, and enhance long-term sustainability.

Specifically, the transactions will ensure the steady availability of key raw materials and intermediates required for API production, thereby supporting business expansion and improved profitability.

All transactions shall be conducted in the ordinary course of business and on an arm’s length basis and in accordance with the Company’s Related Party Transactions Policy.</td></tr>
<tr><td>7</td><td>Details of the promoter(s)/ director(s) / key managerial personnel of the Company who have interest in the transaction, whether directly or indirectly.

<u>Explanation:</u>
Indirect interest shall mean interest held through any person over which an individual has control.</td><td>As MDPL is a subsidiary, below are the common Directors:
Sl No. Name of Director Shareholding
1) Mr. TVVSN Murthy** 01
2) Mr. TV Praveen** 01
3) Mr. P Sarath Kumar -
** as nominee of the Company</td><td>Although PLPL is a closely held company, there are no common Directors between PLPL and the Company.

The related party relationship arises solely by virtue of the common Promoters/Promoter Group holding and controlling the equity share capital of both companies.</td></tr>
<tr><td>8</td><td>A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.</td><td colspan="2">As and when the Board feels appropriate, valuation report or other external report would be sought in accordance with the Companies Act, 2013 and other relevant laws for undertaking proposed Related Party Transactions.</td></tr>
<tr><td>9</td><td>Other information relevant for decision making.</td><td colspan="2">Based on the nature of transaction, advance for part or full amount of the transaction/ arrangement could be paid in the ordinary course of business.</td></tr>
</table>

**trade advance is against the purchase of good & services.

Part B

Details of specific transactions in addition to Part A

B(1). Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances.

S. No.	Particulars of the information	Information provided by the management	
		Mahi Drugs Private Limited ("MDPL)	Purogene Labs Private Limited ("PLPL")
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process. All the transactions are based on routine requirements and in relation to usual business operations of the Company. These RPTs are in the ordinary course of business with terms and conditions that are generally prevalent in the industry segments and the market that the Company operates in.	
2	Basis of determination of price.	Pricing mechanism has been determined either by benchmarking internal / external comparable contracts / published reports of similar nature.	
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following: a) Amount of Trade advance: b) Tenure: c) Whether same is self-liquidating?:	**Pricing Terms:** The transaction shall be undertaken on terms prevailing in the ordinary course of business and in accordance with general industry practices. **Trade Advance:** The Audit Committee and the Board of Directors, at their respective meetings held on 11th February 2026, approved the grant of trade advance aggregating up to ₹20 Crores. Trade advance are recurring in nature and are extended in the ordinary course of business. Such advance are adjusted against the purchase of goods and/or services and are ordinarily settled or set off within 365 days from the date of payment, in accordance with the mutually agreed commercial terms between the parties.	**Pricing Terms:** The transaction shall be undertaken on terms prevailing in the ordinary course of business and in accordance with general industry practices. **Trade Advance:** The Audit Committee and the Board of Directors, at their respective meetings held on 11th February 2026, approved the grant of trade advance aggregating up to ₹10 Crores. Trade advance are recurring in nature and are extended in the ordinary course of business. Such advance are adjusted against the purchase of goods and/or services and are ordinarily settled or set off within 365 days from the date of payment, in accordance with the mutually agreed commercial terms between the parties.

(Contd.)

B.6 Lease rent receivable:

S. No.	Particulars of the information	Information provided by the management	
		Mahi Drugs Private Limited ("MDPL)	Purogene Labs Private Limited ("PLPL")
1	Bidding or other process, if any, applied for choosing a party for sale, lease or disposal of assets of subsidiary or of unit, division or undertaking of the listed entity.	No bidding process. Registered office of the Company located in Hyderabad have been sub-leased to MDPL for use as its corporate office, enabling both entities to operate from the same premises.	No bidding process. Registered office of the Company located in Hyderabad have been sub-leased to PLPL for use as its Registered office, enabling both entities to operate from the same premises.
2	Basis of determination of price.	Market valuation	
3	Reasons for sale, lease or disposal of assets of subsidiary or of unit, division or undertaking of the Company or disposal of shares of subsidiary or associate.	This arrangement facilitates administrative convenience, operational coordination and optimal utilization of office infrastructure.	
4	Financial track record of the subsidiary / undertaking that is being sold (in case of sale of undertaking, segment level data to be provided) during the last three financial years.	Not applicable	
5	Expected financial impact on the consolidated turnover, net worth and net profits of the listed entity or its subsidiary due to sale of the subsidiary / undertaking.	Not applicable	

Part C

The aforesaid lease arrangement is of a nominal value and does not exceed the prescribed materiality threshold, the disclosures required under Part C(5) of the applicable Industry Standards are not applicable and have, therefore, not been furnished.

Annexure B

Disclosure in accordance with SEBI Circular dated June 26, 2025, on the Industry Standards on "Minimum Information to be provided to the Audit Committee and Shareholders for Approval of Related Party Transactions (RPTs)" ("RPT Industry Standards" or "Standards")

Part A

Minimum information of the proposed RPT, applicable to all RPTs

Details of the material Related Party Transactions with Mahi Drugs Private Limited and Purogene Labs Private Limited, being a related parties of the Company

A(1). Basic details of the related party

S. No.	Particulars of the information	Information provided by the management
1	Name of the related party	ChemWerth Inc
2	Country of incorporation of the related party	USA
3	Nature of business of the related party	ChemWerth is a full service generic drug development and supply company providing high quality Active Pharmaceutical Ingredients to regulated markets worldwide.

A(2). Relationship and ownership of the related party

S. No.	Particulars of the information	Information provided by the management
1	Relationship between the Company and the related party – including nature of its concern (financial or otherwise) and the following:	ChemWerth Inc. is a strategic investor holding 35% equity stake in the Company's subsidiary ("MDPL") and is classified as a related party in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
	● Shareholding of the Company, whether direct or indirect, in the related party.	Nil
	● Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the Company.	Not applicable
	● Shareholding of the related party, whether direct or indirect, in the Company	Nil

(Contd.)

A(3). Details of previous transactions with the related party

S. No.	Particulars of the information	Information provided by the management
1	Total amount of all the transactions undertaken by the Company with the related party during the last financial year.	**Transactions during the year 2025-26:** **Sl No. / Nature of transaction / ₹ in lakhs** 1) Sale of Goods 88.98 2) Sale of Services 25.14 **Total 114.12**
2	Total amount of all the transactions undertaken by the Company with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Not applicable
3	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the Company during the last financial year.	No such default

A(4). Amount of the proposed transaction(s)

S. No.	Particulars of the information	Information provided by the management
1	Amount of the proposed transaction being placed for approval in the meeting of the Audit Committee.	**Sl No. / Nature of transaction / ₹ in lakhs** 1) Purchase of Goods 500 2) Sale of Goods 2,500 3) Sale of Services 1,000 4) Trade advance receivable** 1,500 **Total 5,500**
2	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes, the aforesaid proposed transaction shall qualify as "Material RPT" as per the Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3	Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year	Annual Consolidated Turnover of the Company - **₹33,379.45 lakhs** Value of the proposed transactions – **₹5,500 lakhs** Value of the proposed transactions as a percentage of the Company's annual consolidated turnover for the immediately preceding financial year **– 16.18%**
		**trade advance is against the sale of good & services.

(Contd.)

S. No.	Particulars of the information	Information provided by the management
4	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year	Annual Standalone Turnover of the Subsidiary - **₹5,902.01 lakhs** Value of the proposed transactions – **₹5,500 lakhs** Value of the proposed transactions as a percentage of the subsidiary's annual standalone turnover for the immediately preceding financial year **– 93.19%**
5	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	The related party is a privately held overseas entity and its financial statements are not available with the Company. Accordingly, the relevant disclosures and percentage calculations based on the financial statements of the related party are not available.
6	Financial performance of the related party for the immediately preceding financial year: Explanations: The above information is to be given on standalone basis. If standalone is not available, provide on consolidated basis.	The related party is a privately held overseas entity and its financial statements are not available with the Company. Accordingly, the relevant disclosures and percentage calculations based on the financial statements of the related party are not available.

A(5). Basic details of the proposed transaction

S. No.	Particulars of the information	Information provided by the management
1	Specific type of the proposed transaction	As mentioned in point no. A.4.1
2	Details of each type of the proposed transaction	The transaction involves Sale & Purchase of goods, availing & rendering of Services. The maximum annual value of the proposed transactions is estimated based on the Company's current transactions and future business projections.
3	Tenure of the proposed transaction (tenure in number of years or months to be specified)	Proposed transactions are recurring in nature. However, the approval of the shareholders is being sought for entering into Related Party Transactions for the year 2026-27.
4	Whether omnibus approval is being sought?	No
5	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise	As mentioned in point no. A.4.1. Not applicable.

(Contd.)

S. No.	Particulars of the information	Information provided by the management
6	Justification as to why the RPTs proposed to be entered into are in the interest of the Company.	The proposed Related Party Transactions are in the best interest of the Subsidiary Company and are intended to furtherance of its core business objectives. These arrangements aim to achieve operational synergies, reduce costs, and enhance long-term sustainability. Specifically, the transactions will ensure the steady availability of key raw materials and intermediates required for API production, thereby supporting business expansion and improved profitability. All transactions shall be conducted in the ordinary course of business and on an arm's length basis and in accordance with the Company's Related Party Transactions Policy.
7	Details of the promoter(s)/ director(s) / key managerial personnel of the Company who have interest in the transaction, whether directly or indirectly. Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	Not applicable
8	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	As and when the Board feels appropriate, valuation report or other external report would be sought in accordance with the Companies Act, 2013 and other relevant laws for undertaking proposed Related Party Transactions.
9	Other information relevant for decision making.	Based on the nature of transaction, advance for part or full amount of the transaction/ arrangement could be paid in the ordinary course of business.

Part B

Details of specific transactions in addition to Part A

B(1). Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances.

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process. All the transactions are based on routine requirements and in relation to usual business operations of the Company. These RPTs are in the ordinary course of business with terms and conditions that are generally prevalent in the industry segments and the market that the Company operates in.
2	Basis of determination of price.	Pricing mechanism has been determined either by benchmarking internal / external comparable contracts / published reports of similar nature.
S. No.	**Particulars of the information**	**Information provided by the management**
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following: a) Amount of Trade advance: b) Tenure: c) Whether same is self-liquidating?:	**Pricing Terms:** The transactions shall be undertaken on terms prevailing in the ordinary course of business and in accordance with general industry practices. **Trade Advance:** The Audit Committee and the Board of Directors, at their respective meetings held on 11th February 2026, approved the receipt of trade advances aggregating up to ₹15 Crores. Trade advances are recurring in nature and are extended in the ordinary course of business. Such advances are adjusted against the purchase of goods and/or services and are ordinarily settled or set off within 365 days from the date of payment, in accordance with the mutually agreed commercial terms between the parties.

Printed Matter
Book Post / Courier

If undelivered please return to:

HALEOS LABS LIMITED
(Formerly known as SMS Lifesciences India Limited)
CIN: L74930TG2006PLC050223
Regd. Office: Plot No.19-III, Road No.71, Jubilee Hills,
Opp. Bharatiya Vidya Bhavan Public School, Hyderabad – 500096
Contact no – 40 - 6628 8888 | Email – cs@haleoslabs.com | Website: www.haleoslabs.com